Bruce Cohen, MD
Ophthalmology · Saint Louis, MONPI 1053355107
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.5% of the total across 240 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations.
Across 240 payments — averaging $44.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson Surgical Vision, Inc.$2K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$1K
- Alcon$1K
- Glaukos Corporation$682
- Bausch & Lomb Americas Inc.$515
- plus $4K from 21 others
What the payments were for
- Travel & lodging$8968%
- Food & beverage$9,86392%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 65 | $2,005 |
| Johnson & Johnson Surgical Vision, Inc. | 19 | $1,729 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 31 | $1,126 |
| Alcon | 15 | $1,084 |
| Glaukos Corporation | 5 | $682 |
| Bausch & Lomb Americas Inc. | 11 | $515 |
| Sun Pharmaceutical Industries Inc. | 10 | $447 |
| Tarsus Pharmaceuticals, Inc. | 16 | $446 |
| Ocular Therapeutix, Inc. | 5 | $347 |
| Carl Zeiss Meditec USA, Inc. | 2 | $280 |
| Mallinckrodt Hospital Products Inc. | 9 | $259 |
| Rxsight Inc | 3 | $197 |
| Johnson & Johnson Vision Care, Inc. | 2 | $190 |
| Oyster Point Pharma, Inc. | 6 | $164 |
| Sight Sciences, Inc. | 2 | $153 |
| Harrow Eye, LLC | 6 | $134 |
| Aerie Pharmaceuticals, Inc. | 8 | $132 |
| Ivantis, Inc | 1 | $131 |
| Amgen | 1 | $125 |
| Novartis | 2 | $123 |
| Dompe US, Inc. | 1 | $122 |
| Thea Pharma Inc. | 6 | $122 |
| Coopervision Inc. | 1 | $107 |
| Biotissue Holdings Inc. | 8 | $64 |
| Kala Pharmaceuticals, Inc. | 3 | $58 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Shire North American Group Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis Symfony IOL$1,278
- Tecnis 1-piece IOL$1,157
- Tecnis 3-piece IOL$1,157
- Tecnis Symfony Toric IOL$1,157
- DEXTENZA$628
- Hydrus Microstent$402
- DURYSTA$331
- AcrySof$242
- CEQUA$240
- enVista MX60 IOL$238
- XIIDRA$229
- STELLARIS$223
- ENVISTA$216
- VERACITY SURGICAL$204
- ReSure Sealant$170
- iStent infinite Trabecular Micro-Bypass System Model iS3$151
- iS3-iStent infiniteTrabecular Micro-Bypass System Model iS3$151
- iDose$150
- TRYPTYR$150
- Acuvue$146
How this compares
$10,779 in reported general payments places this provider in the 85th percentile of 286 ophthalmology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 172 | $94,942 |
| RestasisCyclosporine | 39 | $38,929 |
| MieboPerfluorohexyloctane/Pf | 26 | $23,963 |
| XdemvyLotilaner | 11 | $21,485 |
| ProlensaBromfenac Sodium | 61 | $21,274 |
| Prednisolone Acetate | 333 | $12,316 |
| VyzultaLatanoprostene Bunod | 24 | $12,082 |
| Alphagan PBrimonidine Tartrate | 17 | $8,630 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 36 | $5,423 |
| Brinzolamide | 16 | $4,016 |
| MoxifloxacinMoxifloxacin Hcl | 189 | $3,946 |
| Brimonidine Tartrate | 65 | $3,854 |
| Bromfenac Sodium | 20 | $3,606 |
| Latanoprost | 346 | $2,455 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 16 | $1,568 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P | $2,005 | $142,500228 claims |
| Bausch & Lomb Americas Inc.Miebo, Vyzulta | $515 | $36,04650 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $446 | $21,48511 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $1,126 | $21,27461 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 286 ophthalmology providers in Missouri.
Other ophthalmology in Saint Louis
- Ranjan MalhotraSaint Louis$809K
- Gregg BerdySaint Louis$360K
- Rajendra ApteSaint Louis$112K
- Ian PithaSaint Louis$85K
- Senthil KrishnasamySaint Louis$46K
- Navin TekwaniSaint Louis$34K
- Steven LeeSaint Louis$33K
- John GalanisSaint Louis$20K
- Waseem AnsariSaint Louis$9K
- Sean EdelsteinSaint Louis$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.